Cisplatin + Etoposide

From OncoWiki
Jump to: navigation, search

Indication

Extensive stage

Regimen 1

  • Cisplatin 80 mg/m2 iv d1
  • Etoposide (VP-16) 80 mg/m2/d iv d1-3
  • Q3w

References

Ihde DC et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 1994; 12:2022

Regimen 2

  • Cisplatin 80 mg/m2 iv d1
  • Etoposide (VP-16) 100 mg/m2/d iv d1-3
  • Q3w x 4 cycles

References

Echcrdt JR et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24:2044

Noda K et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Eng J Med 2002; 346:85

Regimen 3

  • Cisplatin 60 mg/m2 iv d1
  • Etoposide 120 mg/m2/d iv d1-3
  • Q3w

References

Hanna N et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038

Regimen 4

  • Cisplatin 25 mg/m2/d iv d1-3
  • Etoposide (VP-16) 80 mg/m2/d iv d1-3
  • Filgrastim (Neupogen) support
  • Q3-4w x 4 cycles

References

Okamoto H et al. Randomized phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97:162